Attorneys for Mylan Laboratories said the generic drug maker will appeal a ruling barring it from marketing a generic version of Pfizer's popular high blood pressure medication, Norvasc. Pfizer sued Mylan in 2002, claiming Mylan infringed on its patent for Norvasc. Mylan acknowledged infringing on the patent, but said it was invalid because it contained the wrong formula. A trial on the lawsuit was held in November and, on Tuesday, a U.S. District judge ruled in Pfizer's favor.
March 01, 2007 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
Attorneys for Mylan Laboratories Inc. said the generic drug maker will appeal a ruling barring it from marketing a generic version of Pfizer Inc.’s popular high blood pressure medication, Norvasc.
Pfizer sued Mylan in 2002, claiming Mylan infringed on its patent for Norvasc. Mylan acknowledged infringing on the patent, but said it was invalid because it contained the wrong formula.
Presented by BigVoodoo
Join General Counsel and Senior Legal Leaders at the Premier Forum Designed For and by General Counsel from Fortune 1000 Companies
Women, Influence & Power in Law Awards honors women lawyers who have made a remarkable difference in the legal profession.
WIPL is the original global forum facilitating women-to-women exchange on leadership and legal issues.
Associate attorney position at NJ Immigration Law firm: Leschak & Associates, LLC, based in Freehold, NJ, is looking for a full time ass...
Javerbaum Wurgaft, a large civil litigation firm with nine (9) offices, seeks: Plaintiff Personal Injury Attorney for Northern New Jersey of...
Exciting Career Opportunities at Nuzzo & Roberts! Nuzzo & Roberts, a leading mid-sized insurance defense firm based in Cheshire, CT...
